Kyverna Therapeutics, Inc.
Tremor tracks 2 of its cancer trials.
Company-wide warning signs
These add points to every one of this company's trials.
Trials
- KYTXKyverna Therapeutics0Calm
KYSA-6: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy, in Patients With Generalized Myasthenia Gravis
Signing up patientsPhase 2/366 patientsMain results: Sep 2027 - KYTXKyverna Therapeutics0Calm
KYSA-7: A Study of Anti-CD19 CAR T-Cell Therapy, in Subjects With Refractory Primary and Secondary Progressive Multiple Sclerosis
Running, no new patientsPhase 2120 patientsMain results: Apr 2027
Key executives leaving
From the last 12 months of the company's SEC reports.
Insider trades (last 6 months)
“Insiders” are executives, board members, and big shareholders. Many of their sales are pre-planned: scheduled months ahead under a legal plan (called 10b5-1), so they usually say little. Tremor only counts sales that weren't pre-planned.
0 sales (0 not pre-planned) · 0 purchases
Recent SEC filings
Public companies must report important news and their finances to the SEC, the US agency that oversees the stock market.
- Shared information with investorsNews report (8-K)Sep 24, 2026
- Quarterly reportQuarterly report (10-Q)Aug 11, 2026
- Shared quarterly resultsNews report (8-K)Aug 11, 2026
- Signed a major agreement; Shared information with investorsNews report (8-K)Jul 27, 2026
- Signed a major agreementNews report (8-K)Jul 9, 2026